Propoxyphene Compound-65

   
Google
 
Web NewDrugInformation.com

Propoxyphene Compound-65


Drug - Propoxyphene Compound-65
The trade name of the product as shown on the labeling.

Dosage - CAPSULE; ORAL
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Aspirin; Caffeine; Propoxyphene Hydrochloride
Multiple ingredients are in alphabetical order.

Strength - 389MG;32.4MG;65MG
The potency of the active ingredient(s), Aspirin; Caffeine; Propoxyphene Hydrochloride. May repeat for multiple part products.

Applicant - SANDOZ
The firm name holding legal responsibility for Propoxyphene Compound-65. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 083101
The FDA assigned number to Propoxyphene Compound-65. Format is nnnnnn.

Product Number - 002
The FDA assigned number to identify Propoxyphene Compound-65. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Jun 24, 1985
The date Propoxyphene Compound-65 was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - No
The pioneer or innovator of Propoxyphene Compound-65. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - DISCN
The group or category of approved drugs Propoxyphene Compound-65 is in. Format is RX, OTC, DISCN.

Applicant Full Name - Sandoz Inc
The full name of the firm holding legal responsibility for the new application of Propoxyphene Compound-65.

Propoxyphene Compound-65